HT
CYTK icon

Headlands Technologies’s Cytokinetics CYTK Stock Holding History

Headlands Technologies’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4,199
Closed -$267K – 775
2025
Q4 		$267K Buy
+4,199
New +$261K 0.02% 538
2025
Q1 		– Sell
-2,067
Closed -$97.2K – 1222
2024
Q4 		$97.2K Buy
+2,067
New +$107K 0.01% 669
2024
Q1 		– Sell
-10,508
Closed -$877K – 1301
2023
Q4 		$877K Buy
+10,508
New +$381K 0.26% 85

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Headlands Technologies's CYTK Position: Q1 2026 in Review

Headlands Technologies sold out of Cytokinetics (CYTK) in Q1 2026, closing a stake of 4,199 shares — an estimated $267K sold.

Headlands Technologies first reported a position in CYTK in Q4 2023 and held it in 3 quarters. The position peaked at $877K in Q4 2023. 440 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

  • Headlands Technologies reported no remaining Cytokinetics position as of Q1 2026 after selling out during the quarter.
  • Headlands Technologies sold 4,199 Cytokinetics shares in Q1 2026, an estimated $267K.
  • Headlands Technologies first reported a position in Cytokinetics in Q4 2023 and held it in 3 quarters.
  • Headlands Technologies's Cytokinetics position peaked at $877K in Q4 2023.
  • 440 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Headlands Technologies's 13F filing for Q1 2026, filed 13 May 2026.